News & Updates

As patients increasingly turn to artificial intelligence for information about their symptoms, clinicians are encountering a new dynamic in the consulting room. Dr Emma Green and Dr Blesset Nkambule explore the benefits and medicolegal risks of AI-assisted self-diagnosis, and wha...

Hypertension remains one of the most important modifiable cardiovascular risk factors worldwide, yet rates of diagnosis, treatment, and control remain inadequate. Contemporary management increasingly extends beyond achieving a target reading, incorporating accurate measurement, c...

Low-density lipoprotein cholesterol remains central to atherosclerotic cardiovascular disease prevention, but contemporary lipid assessment extends beyond a single measurement. New guidance incorporates lipoprotein(a), apolipoprotein B, triglyceride-rich particles, coronary arter...

Heart failure management has moved beyond a uniform approach based largely on left ventricular ejection fraction. Earlier implementation of guideline-directed therapy, sodium-glucose cotransporter 2 inhibitors, expanding treatment options for preserved ejection fraction, and grea...

Over the past 30 years, atrial fibrillation management has shifted from a predominantly drug-centred approach towards earlier rhythm control, increasingly sophisticated catheter ablation, and more individualised treatment. Yet anti-arrhythmic drugs remain integral to contemporary...

Incretin-based therapies are reshaping the management of type 2 diabetes and obesity. Once regarded primarily as glucose-lowering medicines, glucagon-like peptide-1 receptor agonists and newer dual-agonist therapies now offer substantial weight reduction and, in selected populati...

Perhaps the greatest value of the CKM concept is not the creation of another diagnostic label. It is the change in clinical perspective it encourages. A patient with obesity, T2D, albuminuria, hypertension, and early HF does not have five unrelated problems.

Metabolic dysfunction-associated steatotic liver disease is closely intertwined with obesity, type 2 diabetes, dyslipidaemia, and cardiovascular disease. Greater emphasis on fibrosis risk, non-invasive assessment, weight management, and emerging pharmacological therapies is chang...

As National Obesity Week approaches, the treatment conversation is increasingly about matching the right intervention to the right patient. Within an expanding therapeutic landscape, phentermine retains a defined role as an adjunct to a medically monitored programme of nutrition,...

Dr Wayne May is a UCT graduate and specialist endocrinologist in full-time private practice at Kingsbury Hospital, Cape Town. He practises at the multidisciplinary Diabetes Life Clinic and has a longstanding interest in obesity and metabolic medicine. He helped establish the Cape...

Across this month’s cardiology and endocrinology coverage, one idea keeps returning: organ risk rarely develops in isolation. The CKM framework offers a clear way to show patients and teams how metabolic, kidney, liver, and cardiovascular risk can build on one another.¹,²

An 82-year-old woman presenting with recurrent severe upper abdominal pain was found to have multiple hydatid cysts involving the liver, lungs, and brain. When follow-up imaging showed enlargement of a liver cyst and concern about possible rupture, laparoscopic decompression offe...